These sites can be targeted for the development of therapeutic molecules to treat BK channel associated pathologies including drug therapies for BK channel associated diseases such as neurological disorders associated with either gain-of-function or loss-of-function BK mutations7 or impaired urinary bladder control11. The gene discussed is KCNMA1; the disease is nervous system disorder.